Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca's Atacand Heart Failure Indication Clears FDA Ahead Of Cmte. Review

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency approves candesartan for treatment of heart failure to reduce cardiovascular mortality and hospitalizations. The angiotensin receptor blocker is the first product in its class to receive the claim. Approval comes two days before an FDA advisory panel review.
Advertisement

Related Content

AstraZeneca's Atacand Adds ACE Inhibitor Combo Claim For Heart Failure
AstraZeneca's Atacand Adds ACE Inhibitor Combo Claim For Heart Failure
Atacand Use With ACE Inhibitors Recommended For Heart Failure Treatment
Atacand Use With ACE Inhibitors Recommended For Heart Failure Treatment
Atacand Advisory Cmte. To Focus On Concomitant Use With ACE Inhibitors
Atacand Advisory Cmte. To Focus On Concomitant Use With ACE Inhibitors
Atacand Advisory Cmte. To Focus On Concomitant Use With ACE Inhibitors
AstraZeneca Submits Atacand For Heart Failure: First ARB To Show Mortality Benefit
AstraZeneca Submits Atacand For Heart Failure: First ARB To Show Mortality Benefit

Topics

Advertisement
UsernamePublicRestriction

Register

PS061613

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel